Feature|Articles|March 12, 2026

Elucidating Treatment Selection for Metastatic HSPC at ASCO GU 2026

Fact checked by: Russ Conroy, Justin Mancini

By harnessing investigator-generated data, companion diagnostics, and biomarker-directed treatment selection, clinicians can optimize care for HSPC.

In an oral session at the 2026 American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU), Christopher Sweeney, MBBS, DHS, FRACP, director of the South Australian immunoGenomics Cancer Institute of Adelaide University, discussed optimal treatment selection for patients with metastatic hormone-sensitive prostate cancer (HSPC).¹ Specifically, he highlighted 4 major points when focusing on treatment for these patients: